Floatz logo

APAMISTAMAB-B10-ASTATINE AT-211

Myelodysplastic Syndrome With Excess Blasts

Fred Hutchinson Cancer Centerantibody_drug_conjugatePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Myelodysplastic Syndrome With Excess Blasts cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
University of Southern California
Phase 3BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

APAMISTAMAB-B10-ASTATINE AT-211 is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
mixed phenotype acute leukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →